Literature DB >> 32319702

Cold-stored whole blood in a Norwegian emergency helicopter service: an observational study on storage conditions and product quality.

Christopher Bjerkvig1,2,3, Joar Sivertsen4, Hanne Braathen4, Turid Helen Felli Lunde4, Geir Strandenes4,5, Jörg Assmus6, Tor Hervig3,4, Andrew Cap7, Einar K Kristoffersen3,4, Theodor Fosse1,2,3, Torunn Oveland Apelseth4,8.   

Abstract

BACKGROUND: Increasing numbers of emergency medical service agencies and hospitals are developing the capability to administer blood products to patients with hemorrhagic shock. Cold-stored whole blood (WB) is the only single product available to prehospital providers who aim to deliver a balanced resuscitation strategy. However, there are no data on the safety and in vitro characteristics of prehospital stored WB. This study aimed to describe the effects on in vitro quality of storing WB at remote helicopter bases in thermal insulating containers. STUDY DESIGN AND METHODS: We conducted a two-armed single-center study. Twenty units (test) were stored in airtight thermal insulating containers, and 20 units (controls) were stored according to routine procedures in the Haukeland University Hospital Blood Bank. Storage conditions were continuously monitored during emergency medical services missions and throughout remote and blood bank storage. Hematologic and metabolic variables, viscoelastic properties, and platelet (PLT) aggregation were measured on Days 1, 8, 14, and 21.
RESULTS: Storage conditions complied with the EU guidelines throughout remote and in-hospital storage for 21 days. There were no significant differences in PLT aggregation, viscoelastic properties, and hematology variables between the two groups. Minor significantly lower pH, glucose, and base excess and higher lactate were observed after storage in airtight containers.
CONCLUSION: Forward cold storage of WB is safe and complies with EU standards. No difference is observed in hemostatic properties. Minor differences in metabolic variables may be related to the anaerobic conditions within the thermal box.
© 2020 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.

Entities:  

Year:  2020        PMID: 32319702     DOI: 10.1111/trf.15802

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Prehospital Whole Blood Transfusion Programs in Norway.

Authors:  Christopher Kalhagen Bjerkvig; Geir Strandenes; Tor Hervig; Geir Arne Sunde; Torunn Oveland Apelseth
Journal:  Transfus Med Hemother       Date:  2021-10-22       Impact factor: 3.747

2.  The Evolution of Blood Product Use in Trauma Resuscitation: Change Has Come.

Authors:  Mark H Yazer
Journal:  Transfus Med Hemother       Date:  2021-11-02       Impact factor: 3.747

Review 3.  There and back again: the once and current developments in donor-derived platelet products for hemostatic therapy.

Authors:  Valery J Kogler; Moritz Stolla
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

4.  Effects of the COVID-19 pandemic on supply and use of blood for transfusion.

Authors:  Simon J Stanworth; Helen V New; Torunn O Apelseth; Susan Brunskill; Rebecca Cardigan; Carolyn Doree; Marc Germain; Mindy Goldman; Edwin Massey; Daniele Prati; Nadine Shehata; Cynthia So-Osman; Jecko Thachil
Journal:  Lancet Haematol       Date:  2020-07-03       Impact factor: 18.959

5.  Implementation of a dual platelet inventory in a tertiary hospital during the COVID-19 pandemic enabling cold-stored apheresis platelets for treatment of actively bleeding patients.

Authors:  Hanne Braathen; Kristin G Hagen; Einar K Kristoffersen; Geir Strandenes; Torunn O Apelseth
Journal:  Transfusion       Date:  2022-06-22       Impact factor: 3.337

6.  The Norwegian blood preparedness project: A whole blood program including civilian walking blood banks for early treatment of patients with life-threatening bleeding in municipal health care services, ambulance services, and rural hospitals.

Authors:  Torunn Oveland Apelseth; Mirjana Arsenovic; Geir Strandenes
Journal:  Transfusion       Date:  2022-06-25       Impact factor: 3.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.